The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: An NMR evaluation

Journal of Inorganic Biochemistry

Volumn 98, Issue 2, 2004, Pages 402-412

  Bacac, Marina ^a,b,c   Hotze, Anna C G ^a   Van Der Schilden, Karlijn ^a   Haasnoot, Jaap G ^a   Pacor, Sabrina ^b   Alessio, Enzo ^b   Sava, Gianni ^b,c   Reedijk, Jan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Callerio Foundation   (Italy)

Author keywords

Cell cycle arrest at G2 M phase; Coordination to 9 methyladenine; Hydrolysis; NAMI A; Ruthenium

Indexed keywords

9 METHYLADENINE; ANTINEOPLASTIC AGENT; CHLORIDE; RUTHENIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS KINETICS; MITOSIS INHIBITION; PH MEASUREMENT; PROTEIN CONTENT; PROTON NUCLEAR MAGNETIC RESONANCE;

MURINAE;

EID: 0345830489     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinorgbio.2003.12.003     Document Type: Article

References (27)

1. Clarke M.J., Zhu F., Frasca D.R. Chem. Rev. 99:1999;2511-2533.
2. Reedijk J. Proc. Natl. Acad. Sci. USA. 100:2003;3611-3616.
3. Sava G., Bergamo A. Int. J. Oncol. 17:2000;353-365.
4. Alessio E., Balducci G., Lutman A., Mestroni G., Calligaris H., Attia W.M. Inorg. Chim. Acta. 203:1993;205-217.
5. Sava G., Alessio E., Bergamo A., Mestroni G. Clarke M.J., Sadler P.J. Sulfoxide Ruthenium Complexes: Non Toxic Tools for the Selective Treatment of Solid Tumor Metastases. 1999;143-170.
6. Sava G., Zorzet S., Peressin L., Mestroni G., Zassinovich G., Bontempi A. Inorg. Chim. Acta. 137:1987;69-71.
7. E. Alessio, W. Attia, M. Calligaris, D. Cauci, L. Dolzani, G. Mestroni, C. Monti-Bragadin, G. Nardin, F. Quadrifoglio, G. Sava, M. Tamaro, S. Zorzet, in: M. Nicolini (ed.), Boston, Platinum and Other Metal Coordination Compounds in Cancer Chemotheraphy, Nÿhoff 1988, pp. 617-633.
8. Bergamo A., Gagliardi R., Scarcia V., Furlani A., Alessio E., Mestroni G., Sava G. J. Pharmacol. Exp. Ther. 289:1999;559-564.
9. Pacor S., Vadori M., Vita F., Bacac M., Soranzo M.R., Zabucchi G., Sava G. Anticancer Res. 21:2001;2523-2530.
10. Berners Price S.J., Sadler P.J. Coord. Chem. Rev. 151:1996;1-40.
11. Malina J., Novakova O., Keppler B.K., Alessio E., Brabec V. J. Biol. Inorg. Chem. 6:2001;435-445.
12. Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M., Boccarelli A. Metal Based Drugs. 1:1993;41-63.
13. Küng A., Pieper T., Wissiack R., Rosenberg E., Keppler B.K. J. Biol. Inorg. Chem. 6:2001;292-299.
14. Izatt R.M., Christensen J.J., Rytting J.H. Chem. Rev. 71:1971;439-481.
15. Inagaki K., Kuwayama M., Kidani Y. J. Inorg. Biochem. 16:1982;59-65.
16. Spiro T.G. Nucleic Acid-Metal Ion Interactions. 1980;Wiley, New York.
17. Lippard S.J. Progress in Inorganic Chemistry. 1977;Wiley, New York.
18. Velders A.H., van der Geest B., Kooijman H., Spek A.L., Haasnoot J.G., Reedijk J. Eur. J. Inorg. Chem. 2001;369-372.
19. Hotze A.C.G., Broekhuisen M.E.T., Velders A.H., van der Schilden K., Haasnoot J.G., Reedijk J. Eur. J. Inorg. Chem. 2002;369-376.
20. Sava G., Bergamo A., Zorzet S., Gava B., Casarsa C., Cocchietto M., Furlani A., Scarcia V., Serli B., Iengo E., Alessio E., Mestroni G. Eur. J. Cancer. 38:2002;427-435.
21. Taqui Khan M.M., Ramachandraiah G., Shukla R.S. Inorg. Chem. 27:1988;3274-3278.
22. Bergamo A., Zorzet S., Gava B., Sorc A., Alessio E., Iengo E., Sava G. Anti-cancer Drugs. 11:2000;665-672.
23. Messori L., Orioli P., Vullo D., Alessio E., Iengo E. Eur. J. Biochem. 267:2000;1206-1213.
24. Talman E.G., Brüning W., Reedijk J., Spek A.L., Veldman N. Inorg. Chem. 36:1997;854-861.
25. Tada H., Shiho O., Kuroshima, Koyama K., Tsukamoto M. J. Immunol. Meth. 93:1986;157-165.
26. Tamura H., Arai T., Nagase M., Ichinose N. Bunseki Kagaku. 41:1992;T13-T18.
27. Cocchietto M., Sava G. Pharmacol. Toxicol. 87:2000;193-197.